Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-year open-label extension study of zoledronic acid twice yearly in osteoporotic children on glucocorticoids
2010-020399-41Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zoledronic acid in osteoporosis, sponsored by Novartis. Primary endpoint: Long-term safety of zoledronic acid over additional 12 months. Started Jan 2013; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2010-020399-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020399-41.